Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; VET3 TGI (Primary) ; VET3 TGI (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Sarcoma; Solid tumours; Thymoma; Uterine cancer
  • Focus Adverse reactions
  • Acronyms STEALTH-001
  • Sponsors KaliVir Immunotherapeutics

Most Recent Events

  • 25 Mar 2025 According to KaliVir Immunotherapeutics media release, company announced a presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL.
  • 08 Oct 2024 According to KaliVir Immunotherapeutics media release, first patient has been dosed in this study.
  • 20 Sep 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top